转移性激素敏感前列腺癌原发灶的治疗：尚未准备好成为标准治疗。
Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care.
机构信息
Department of Urology, Orange Health Service, Orange, Australia.
Department of Urology, The University of Texas M.D. Anderson Cancer Centre, Houston, TX, USA.
出版信息
Eur Urol. 2019 Nov;76(5):543-545. doi: 10.1016/j.eururo.2019.06.014. Epub 2019 Jun 25.
Abstract
Retrospective studies in selected patients have demonstrated a survival benefit with prostatectomy or radiotherapy (RT) of the primary tumor in metastatic hormone-sensitive prostate cancer (mHSPC). However, there is currently not enough evidence to recommend RT to the primary tumor as the standard of care for patients treated with androgen deprivation therapy plus abiraterone or docetaxel for low-volume mHSPC.
摘要
回顾性研究表明，对于转移性激素敏感性前列腺癌（mHSPC）患者，前列腺切除术或放疗（RT）原发肿瘤可带来生存获益。然而，目前尚无足够证据推荐 RT 作为标准治疗方案，用于接受雄激素剥夺治疗联合阿比特龙或多西他赛治疗低容量 mHSPC 患者的原发肿瘤。
相似文献
1
Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care.转移性激素敏感前列腺癌原发灶的治疗：尚未准备好成为标准治疗。
Eur Urol. 2019 Nov;76(5):543-545. doi: 10.1016/j.eururo.2019.06.014. Epub 2019 Jun 25.
2
The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.转移性激素敏感型前列腺癌的演变格局：对添加多西他赛或阿比特龙进行雄激素剥夺治疗的证据的批判性评价。
Prostate Cancer Prostatic Dis. 2018 Sep;21(3):306-318. doi: 10.1038/s41391-017-0014-9. Epub 2017 Dec 20.
3
Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation.初诊时伴有转移性疾病的新诊断前列腺癌患者的当代管理
Curr Urol Rep. 2018 Aug 13;19(10):79. doi: 10.1007/s11934-018-0835-7.
4
Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm.转移性激素敏感型前列腺癌（mHSPC）的管理：一个不断发展的治疗范例。
Curr Treat Options Oncol. 2019 Jul 9;20(9):69. doi: 10.1007/s11864-019-0668-8.
5
[Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer].多西他赛或阿比特龙联合雄激素剥夺疗法治疗转移性前列腺癌
Urologe A. 2019 Oct;58(10):1185-1197. doi: 10.1007/s00120-019-0953-y.
6
[Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer].雄激素剥夺疗法联合化疗±雄激素受体靶向药物治疗转移性激素敏感性前列腺癌
Urologie. 2023 Apr;62(4):360-368. doi: 10.1007/s00120-023-02029-0. Epub 2023 Feb 10.
7
Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!阿比特龙还是多西他赛用于去势敏感性转移性前列腺癌？这是个问题！
Eur Urol. 2018 Jan;73(1):147-148. doi: 10.1016/j.eururo.2017.07.030. Epub 2017 Aug 8.
8
Systemic treatment options for metastatic hormone-sensitive prostate cancer: making sense of the data.转移性激素敏感型前列腺癌的系统治疗选择：解读数据。
Curr Opin Urol. 2020 Jul;30(4):576-583. doi: 10.1097/MOU.0000000000000778.
9
Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).转移性疾病出现的时间和疾病体积对转移性激素敏感性前列腺癌（mHSPC）具有预后意义。
Prostate. 2018 Sep;78(12):889-895. doi: 10.1002/pros.23645. Epub 2018 Apr 29.
10
Treatment of Primary in Metastatic Prostate Cancer: What Is the Standard of Care?转移性前列腺癌的原发灶治疗：标准治疗方法是什么？
Cancer J. 2020 Jan/Feb;26(1):83-86. doi: 10.1097/PPO.0000000000000430.
引用本文的文献
1
Efficacy and safety evaluation of androgen deprivation therapy-based combinations for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis.基于雄激素剥夺疗法的联合治疗转移性去势敏感性前列腺癌的疗效和安全性评价：系统评价和网络荟萃分析。
Br J Cancer. 2024 Nov;131(8):1363-1377. doi: 10.1038/s41416-024-02823-3. Epub 2024 Sep 2.
本文引用的文献
1
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.新诊断转移性前列腺癌原发肿瘤放疗（STAMPEDE）：一项随机对照 3 期试验。
Lancet. 2018 Dec 1;392(10162):2353-2366. doi: 10.1016/S0140-6736(18)32486-3. Epub 2018 Oct 21.
2
Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.在一项前瞻性随机临床试验中，比较单纯去势治疗与去势治疗联合前列腺同期放疗对原发性骨转移前列腺癌患者生存的影响：来自 HORRAD 试验的数据。
Eur Urol. 2019 Mar;75(3):410-418. doi: 10.1016/j.eururo.2018.09.008. Epub 2018 Sep 25.
3
Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.美国转移性前列腺癌的过去、现在和未来发病率及负担。
Eur Urol Focus. 2018 Jan;4(1):121-127. doi: 10.1016/j.euf.2017.10.014. Epub 2017 Nov 20.
4
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.阿比特龙用于既往未接受过激素治疗的前列腺癌患者
N Engl J Med. 2017 Jul 27;377(4):338-351. doi: 10.1056/NEJMoa1702900. Epub 2017 Jun 3.
5
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.阿比特龙联合泼尼松治疗转移性去势敏感性前列腺癌。
N Engl J Med. 2017 Jul 27;377(4):352-360. doi: 10.1056/NEJMoa1704174. Epub 2017 Jun 4.
6
Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.新诊断转移性前列腺癌患者接受雄激素剥夺治疗联合前列腺放射治疗可提高生存率。
J Clin Oncol. 2016 Aug 20;34(24):2835-42. doi: 10.1200/JCO.2016.67.4788. Epub 2016 Jun 20.
7
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.多西他赛、唑来膦酸或两者联合添加至前列腺癌一线长期激素治疗（STAMPEDE）：一项适应性、多组、多阶段、平台随机对照试验的生存结果
Lancet. 2016 Mar 19;387(10024):1163-77. doi: 10.1016/S0140-6736(15)01037-5. Epub 2015 Dec 21.
8
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.转移性激素敏感性前列腺癌的化学激素疗法
N Engl J Med. 2015 Aug 20;373(8):737-46. doi: 10.1056/NEJMoa1503747. Epub 2015 Aug 5.
9
Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study.前列腺癌合并少量骨转移患者的减瘤性根治性前列腺切除术：一项可行性及病例对照研究的结果
J Urol. 2015 Mar;193(3):832-8. doi: 10.1016/j.juro.2014.09.089. Epub 2014 Sep 22.
10
Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study.基于 SEER 数据库的研究：在诊断为转移性前列腺癌的患者中，确定局部治疗原发肿瘤的最佳候选者。
Eur Urol. 2015 Jan;67(1):3-6. doi: 10.1016/j.eururo.2014.08.056. Epub 2014 Sep 10.
Zotero 插件